Verve Therapeutics Halts Enrollment of Heart-1 PCSK9 Gene Therapy Trial

Verve Therapeutics announced plans to voluntary pause enrollment of the Heart-1 trial, citing an adverse event and consultation with DSMB, with plans to shift focus to VERVE-102 and Heart-2 trial.

Related Keywords

New Zealand ,United Kingdom ,Canada ,United States ,American ,Sekar Kathiresan ,Andrew Bellinger ,American Heart Association Scientific Sessions ,Verve Therapeutics ,American Heart Association ,Scientific Sessions ,Investigational New Drug Application ,